Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target
Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target
觀看 Cabaletta Bio；聽到交易員流傳坎託·菲茨傑拉德說：“我們不會被這個模糊的'FDA正在調查這個'標題所嚇倒。我們已經接受了各種發展風險” 捍衛買入評級，目標價爲50美元
Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target
觀看 Cabaletta Bio；聽到交易員流傳坎託·菲茨傑拉德說：“我們不會被這個模糊的'FDA正在調查這個'標題所嚇倒。我們已經接受了各種發展風險” 捍衛買入評級，目標價爲50美元